Study of TQB2868, anlotinib, and chemo for first-line pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new combination of drugs (TQB2868, anlotinib, and chemotherapy) as a first treatment for metastatic pancreatic cancer that has spread. It may help if you have not had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer) that has spread to other parts of the body.
- You are between 18 and 75 years old.
- You have not received any previous cancer treatment for metastatic disease, though you may qualify if you had prior treatment before the cancer spread and it progressed more than 6 months after that treatment ended.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1) and are expected to live at least 3 months.
- Your major organs are working well, and you agree to use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (TQB2868 injection plus anlotinib capsules) compared to standard chemotherapy for people with pancreatic cancer that has spread to other parts of the body and has not been treated before.
This trial tests a new drug (TQB2916) combined with standard chemotherapy (gemcitabine and nab-paclitaxel) as a first treatment for metastatic pancreatic cancer. It aims to see if the combination works better than chemo alone.
This trial tests a combination of anlotinib (a targeted drug), benmelstobart (an immunotherapy), and AG chemotherapy as a first treatment for advanced pancreatic cancer that has spread to other parts of the body. The goal is to see if this triple therapy can help shrink or control the cancer better than standard treatments.
This trial tests a combination of immunotherapy (penpulimab), a targeted therapy (anlotinib), and two chemotherapy drugs (nab-paclitaxel and gemcitabine) as a first treatment for pancreatic cancer that has spread. It aims to see if this new combination works better than standard care.
This trial tests a new combination of three drugs (QL1706, chidamide, and AG) as the very first treatment for people with metastatic pancreatic cancer. The goal is to see if this combination is safe and effective, and it may offer a new option for those who have not had any prior therapy.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Pancreatic Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.